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ABSTRACT 
 Neurofibromatosis 2 (NF2) is a dominantly inherited disorder, which predisposes to 
multiple tumours of the nervous system, typically schwannomas and meningiomas. 
Biallelic inactivation of the NF2 gene occurs both in sporadic and NF2-related 
schwannomas and in most meningiomas.  
The NF2 gene product merlin (or schwannomin) is structurally related to the ERM 
proteins, ezrin, radixin and moesin, which act as molecular linkers between the actin 
cytoskeleton and the plasma membrane. Merlin partly colocalizes with the ERM 
proteins in regions of dynamic cytoskeletal remodeling and forms heterodimers with 
ezrin. Like ezrin, merlin undergoes conformational regulation, which is at least 
partially mediated by phosphorylation. Merlin is a tumor suppressor that participates 
in cell cycle regulation. Merlin’s phosphorylation status appears to be associated with 
its tumour suppressor activity, i.e. non-phosphorylated merlin functions as a tumour 
suppressor, whereas protein phosphorylation results in loss of functional activity. At 
least two kinases, p21-activated kinase (PAK) and cyclic AMP (cAMP) dependent 
protein kinase (PKA), have been shown to phosphorylate merlin.  
This thesis study was initiated to investigate merlin’s role as a tumor suppressor and 
growth inhibitor. These studies show, that like many other tumor suppressors, also 
merlin is targeted to the nucleus at some stages of the cell cycle. Merlin’s nuclear 
localization is regulated by cell cycle phase, contact inhibition and adhesion. In 
addition, a potential nuclear binding partner for merlin was identified, Human 
Enhancer of Invasion 10 (HEI10), a cyclin B interacting protein, which functions as 
an ubiquitin ligase for cyclin B and controls its accumulation during cell cycle. HEI10 
undergoes nucleo-cytoplasmic shuttling and colocalizes with merlin in the nucleus at 
the G1 phase of the cell cycle and at the plasma membrane during other phases of the 
cell cycle. Increased merlin expression in primary human schwannoma cell cultures, 
results in changes in the subcellular localization of HEI10. Merlin also regulates the 
amount of HEI10 by increasing its degradation.  
Many tumor suppressors interact with microtubules and this thesis work shows that 
also merlin colocalizes with microtubules in mitotic structures. Merlin binds 
microtubules directly, and increases their polymerization in vitro and in vivo. In 
addition, primary mouse Schwann cells lacking merlin displays disturbed microtubule 
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cytoskeleton. This is of interest since cytoskeletal defects occur also in schwannomas 
that are isolated from patients.  
Fourth part of this thesis work began from the notion that in addition to C-terminal 
phosphorylation, PKA phosphorylates also an unidentified site from the merlin N-
terminus. Therefore the N-terminal phosphorylation was investigated further. Our 
studies show that serine 10 is a target for PKA and modulation of this residue regulates 
cytoskeletal organization, lamellipodia formation and cell migration. 
Dephosphorylation of this residue inhibits lamellipodia formation and decreases the 
amount of actin filaments.   
In summary, this thesis work shows that merlin’s role is much more versatile than 
previously thought. It has a yet unidentified role in the nucleus and it participates in 
the regulation of both microtubules and the actin cytoskeleton. These studies have led 
to a better understanding of this enigmatic tumor suppressor, which eventually will aid 




REVIEW OF THE LITERATURE 
1. The Cell-division cycle 
Cells originate from other cells. Cell division is essential for unicellular organisms 
that use it to propagate and for multi-cellular organisms, which need cell division for 
production of the gametes (meiosis) and for growth and development (mitosis). It is 
the method by which a single fertilized egg develops into a mature organism, and by 
which tissue homeostasis is maintained. The somatic cell cycle of all animals consists 
of a series of events that leads to the duplication of all cellular material and to the 
birth of two genetically identical daughter cells. Errors in these finely tuned series of 
events can lead to genetic aberrations and cancer. 
The cell cycle consists of four different phases (Fig. 1): Mitosis (M), Gap 1 (G1), 
Synthesis (S) and Gap 2 (G2). During these four phases the cell must replicate its 
genome, double its mass and duplicate the organelles in the cytoplasm. M phase is the 
physical separation of the chromosomes and cytoplasm to two daughter cells. During 
S phase the cell replicates its genetic material. G1 and G2 phases separate M and S 
phase and prepare the cell for the next phase in its cycle. During G2 the cell doubles 
its mass for the preceding cell cleavage at M phase. By this means daughter cells 
maintain their size during every round of symmetric cell division. Cells that are not 
dividing exit the cell cycle in G1, become quiescent and enter phase G0. The cell-
division cycle is controlled by various checkpoints and the cycle is considered to be 
irreversible.  
Three key classes of molecules regulate the progression of the cell-division cycle: 
cyclins, cyclin-dependent kinases (Cdks) and phosphatases (Hartwell, 2002, Hunt, 
2002, Nurse, 2002, Boutros et al, 2007). Cyclins form the regulatory subunits and the 
Cdks the catalytic subunits of the heterodimer. Together a Cdk-cyclin heterodimer is 
an active kinase, which phosphorylates its downstream targets, ultimately leading to 
cell cycle progression. Phosphatases on the other hand function on the opposite 
manner, by removing phosphate groups from their targets.  Precise timing is also 
important in the regulation of phosphatases during different cell cycle stages. They 
have the power to remove inhibitory phosphates from Cdks (Cdc25 and Calcineurin) 
(Boutros et al, 2007, Kahl & Means, 2004) thus promoting cell cycle progression or to 
remove inhibitory phosphates from cell cycle controllers (such as pRb, protein 
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phosphatase 1) (Tamrakar et al, 2000) thus inhibiting cell cycle progression. Different 
sets of Cdks, cyclins and phosphatases regulate different phases of the cell cycle. The 
amount of cyclins varies in a recurring fashion during cell cycle. For example 
degradation of an M-phase cyclin, cyclin B, is required for exit from mitosis. Yeast 
cells require only one Cdk, which binds all classes of cyclins and drives all phases of 
the cell cycle by changing cyclin partners. Vertebrate cells, however, contain 11 
different Cdks, four key Cdk-cyclin complexes are considered to drive the cell cycle; 
Cdk2-cyclin E complex that governs cell cycle progression from G1 to S phase and 
Cdk1/2-cyclin A that ensures progression through S phase and entry to G2/M, Cdk1-
cyclin B that is needed for mitosis, and Cdk4/5-cyclin D that controls entry into and 
progression of G1, and entry back into the cell cycle from G0 requires the Cdk4/6-
cyclin D complex.  
 
Figure 1. Four phases of the mammalian cell division cycle. The cell cycle consists of four 
distinct phases (G1-S-G2-M), which are normally irreversible. Progression through these 
phases is controlled by Cdks, their cyclin partners and phosphatases. The resting phase is 
called G0. Cell’s genetic material is replicated in S phase, the cell doubles its mass in G2 
phase and the division takes place in M phase. Cdc25 and Calcineurin remove inhibitory 
phosphate groups from Cdks (green arrows).  
 
Cyclin partners do not simply activate Cdk’s; they also direct the kinase to its specific 
targets. As a result, each Cdk-cyclin heterodimer phosphorylates a different set of 
substrates, leading to different outcomes, during different phases of the cell cycle 
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(Bloom & Cross, 2007, Hartwell, 2002, Hunt, 2002, Murray, 2004, Nurse, 2002, 
Wikman & Kettunen, 2006).  
 
2. Genes and cancer 
Cancer is uncontrollable growth of a cell population that originates from normal 
tissue and is able to invade and/or metastasize. The path that leads to a healthy cell 
becoming an invasive cancer cell has many steps that in most cases involve 
consecutive accumulation of genetic changes. Mutations that cause cancer usually 
appear in chromosomal areas, which encode for genes that regulate cell growth. These 
mutations are usually caused by chemical carcinogens, irradiation or by viruses that 
are able to insert their DNA into genome. Mutations may also occur spontaneously 
and it is possible to inherit a mutated gene, which makes a person more susceptible to 
cancer. In these cases cancer can be inherited. Cancer risk increases with age as our 
cells harbor more genetic alterations.  
Cancer cells have many unique characteristics (Fig. 2). They are able to evade 
apoptosis, they have unlimited growth potential due to reactivation of telomerase and 
they do not require growth factors from outside. In addition, cancer cells have faster 
cell cycle rate and their ability to differentiate is altered. They show no contact 
inhibition of growth and they are able to invade neighboring tissues and to 
metastasize and to promote growth of blood vessels 
(http://www.nature.com/nrc/poster/subpathways/index.html) (Kastan, 2007, Sherr & 
McCormick, 2002, Stewart & Weinberg, 2006, Wikman & Kettunen, 2006). 
 
2.1 Oncogenes 
A proto-oncogene is a normal gene that becomes an oncogene as a result of a 
mutation or altered gene expression. Cell growth, cell division, survival and 
differentiation are all processes driven by proto-oncogenes. Typical proto-oncogenes 
are c-Myc and Ras; their mutations are detected in numerous human cancers. C-Myc 
functions normally as a transcription factor that promotes growth and also inhibits 
Cdk inhibitors. However, its functions are heavily dependent on mitogenic signaling. 
Ras on the other hand operates at the membrane where it can initiate multiple 
signaling cascades leading to cell proliferation. Gene duplications, chromosomal 
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translocations and mutations in proto-oncogenes can alter their functions, increasing 
their activity (Hemann & Narita, 2007).  
 
 
Figure 2. Alterations leading to cancer (modified from Hanahan and Weinberg, 2000) 
(Hanahan & Weinberg, 2000).  
 
Recently, microRNAs (miRNAs), a class of non-protein-coding small RNAs, have 
been indicated in the regulation of cell proliferation and apoptosis. They influence 
gene expression by translational repression of their target genes, by mRNA cleavage 
and mRNA decay. These miRNAs are involved in several human cancers, where they 
can act as both oncogenes and tumor suppressors (Dalmay & Edwards, 2006, Zhang 
et al, 2007). 
 
2.2 Tumor suppressor genes 
The discovery of oncogenes proposed the presence of a distinct class of anti-
oncogenes. Over the last 17 years such genes, tumor suppressor genes, have been 
identified (reviewed in Sherr, 2004). Tumor suppressor genes regulate a wide variety 
of cellular functions. They are involved in cell cycle checkpoint responses, detection 
and repair of DNA damage, protein ubiquitination and degradation, mitogenic 
signaling, differentiation, migration, and tumor angiogenesis (Sherr, 2004). Tumor 
suppressor genes provide protection against cancer, and the presence of only a single 
allele of a tumor suppressor gene is in most cases sufficient for its protective function. 
Thus, tumor suppressor genes require a ‘two-hit’ inactivation of both alleles for 
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cancer to develop (Knudson, 1971). In cancers, tumor suppressor genes harbor loss-
of-function mutations or are completely deleted. In hereditary cancer syndromes 
patients carry one inactivated tumor suppressor gene in their germ line and an 
additional somatic mutation, loss-of heterozygosity or an epigenetic mechanism is 
required for the complete loss of gene function. The same tumor suppressor genes are 
frequently mutated in sporadic cancers (Sherr, 2004) and therefore, studying these 
tumor suppressors is beneficial for understanding cancer in general.  
 
2.2.1 Gatekeepers, caretakers and landscapers 
Gatekeepers are tumor suppressor genes that directly regulate cell growth by 
inhibiting it or by promoting cell death. The most classical examples are p53 and pRb, 
the retinoblastoma gene product. pRb was the first tumor suppressor to be 
characterized (Knudson, 1971). It physically interacts with transcription factors and 
represses genes that regulate cell cycle progression, apoptosis and differentiation. It 
prevents cells from entering S phase, serving a cell cycle checkpoint function. 
Phosphorylation of the pRb-protein by mitogen-activated Cdk’s cancels the pRb-
mediated repression. This provides a link between Cdk’s, extracellular signals and 
cell cycle checkpoint control; loss of pRb dissociates the cell cycle from pRb-
mediated extracellular signals (reviewed in Sherr 2004). p53 has a cell cycle 
checkpoint function and it becomes activated by DNA damage. Activation of p53 
causes it to arrest the cell cycle at G1. In response to various cellular stresses such as 
DNA damage and osmotic shock p53 activation leads to a transcriptional response 
that either inhibits cell proliferation or induces apoptosis (Kastan et al, 1991). Many 
cancers have both Rb and p53 inactivated, and for instance human papilloma virus 
can inactivate both tumor suppressors to promote growth (Scheffner et al, 1991, 
Slebos et al, 1994). 
 
Gatekeepers form one point of restriction for tumor formation whereas caretakers 
that, for example, repair DNA or control oncogene expression, act as ‘caretakers’ of 
the genome. Inactivation of a caretaker gene does not promote tumor formation but 
rather increases mutation rate, thereby increasing the probability of tumorigenic 
mutations (Kinzler & Vogelstein, 1997). Therefore, persons carrying germ line 
mutations that affect caretaker tumor suppressor genes are often more prone to 
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tumors, as several mutations are required for the full development of cancer (Hanahan 
& Weinberg, 2000).  
 
Landscapers are cancer susceptibility genes that work through less direct mechanisms 
than gatekeepers or caretakers. The discovery of the landscapers raised essential 
questions about the relation between tumor cells and other cells that together 
constitute a tumor mass. Landscaper defects are not yet well characterized. One 
example of a landscaper effect is found in the juvenile polyposis syndrome. The 
epithelial cells within and surrounding the polyp are initially devoid of neoplastic 
features, but are nevertheless at increased risk of becoming malignant as a result of an 
abnormal microenvironment. This effect can be thought of as a "landscaper" defect in 
the epithelial cells (Kinzler & Vogelstein, 1998).  
 
3. The Cytoskeleton 
The cytoskeleton is essential for all eukaryotic cells. It is formed by three different, 
but interconnected filament structures (Fig. 4): the actin cytoskeleton, microtubules 
and intermediate filaments. The mechanical properties of these structures provide 
shape and strength to the cell, justifying the use of the term cytoskeleton. 
Cytoskeleton also enables the cell to move. In addition, it is required for cell division 
and transport of material inside the cell. The term cytoskeleton is misleading, 
however, in the sense that it suggests a static structure. Cytoskeletal polymers are in 
fact highly dynamic, capable of polymerizing, depolymerizing, and moving within the 
cytoplasm on a time scale of seconds to minutes. Many pathogenic conditions, such as 
invasive cancer, immunity, and host cell infection by pathogens, are linked to defects 
in the cytoskeleton (Fuchs, 1996).   
 
3.1 Actin cytoskeleton 
The actin cytoskeleton forms the ‘muscles’ of a cell and helps to maintain cell shape. 
Actin filaments, also known as microfilaments or F-actin, are polar, helical and 
flexible fibers that are formed through polymerization of globular actin monomers (G-
actin). In muscle tissue actin filaments participate in muscle contraction; in non-
muscle cells actin filaments contribute to various cellular activities such as changes in 
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cell shape, spreading, motility, cytokinesis and polarity. Actin filaments are 
concentrated just beneath the plasma membrane where they form various structures 
that help cells to move. These protrusive structures of the plasma membrane are 
called lamellipodia, filopodia and pseudopodia (Fig. 3). All of these structures contain 
different, specialized actin networks, depending on the accessory proteins 




Figure 3. A schematic presentation of various actin structures. Lamellipodia are a 
characteristic feature at the front, the leading edge, of motile cells. They pull the cell forward 
during cell migration. Lamellipodia are formed by a two-dimensional actin meshwork. Within 
the lamellipodia are protrusions of actin called filopodia. They are formed from actin 
filaments cross-linked into bundles by actin-binding proteins. Filopodia form focal adhesions 
with the substratum, linking them to the cell surface. Stress fibers form when a cell makes 
stable connections with a substrate via integrins (transmembrane adhesion molecules), and 
they provide mechanical support to cells. 
 
3.2 Microtubules 
Microtubules are polymers of tubulin protein found in all dividing eukaryotic cells 
and in most differentiated cell types (Table 1). During cell division, a large dynamic 
array of microtubules, the mitotic spindle, functions to physically segregate the 
chromosomes and to orient the plane of cell cleavage. In non-dividing cells, 
microtubules organize the cytoplasm, position the nucleus and organelles, transport 




Figure 4. A schematic drawing of different cytoskeletal networks and proteins. Actin 
filaments are formed from actin proteins. They supply cell with structural support and enable 
it to move. Microtubules are hollow sylinders made from tubulin dimers (arrow). They 
participate e.g. in mitosis and in vesicle transport. Intermediate filaments provide structural 
support to cells and help to keep epithelial cells together. They are formed from filamentous 
proteins.  
 
Microtubules are more rigid structures than actin filaments with an intrinsic resistance 
to bending and compression. They are hollow cylindrical filaments formed of 
globular α- and β-tubulin dimers. Microtubules are also polar structures, usually with 
the minus end of the microtubule attached to the centrosomes. They are the 
motorways of the cell. They allow intracellular trafficking as vesicles glide along the 
microtubules with the help of motor proteins (such as kinesin and dynein) to their 
targets. Microtubules are very dynamic in most structures, especially the mitotic 
spindle where the non-kinetochore microtubule turnover is only 20 seconds and in 
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kinetochore microtubules 300 seconds (Cimini et al, 2006). These dynamics are 
highly regulated by microtubule-associated proteins (MAPs), especially in neurons, 
where some structures are stabilized and some structures need rapid reformation. 
MAPs are proteins that bind microtubules and induce their 
polymerization/depolymerization (catastrophins). Another proteins are needed for 
microtubule nucleation (γ-tubulin) (reviewed in Desai and Mitchison 1997). To date, 
many tumor suppressors have been shown to bind or regulate microtubules 
(Chaudhuri et al, 1999, Dallol et al, 2004, Fisk et al, 2002, Gregory et al, 1993, 
Hergovich et al, 2003, Jiang & Yeung, 2006, Moshnikova et al, 2006, Sankaran et al, 
2005, Vos et al, 2004).  
Tubulin proteins Microtubule associated proteins (MAPs) 
 
α-tubulin (isotypes I-VI) MAP1A Tau 
β-tubulin (isotypes I-VI) MAP1B Stathmin/OP18 
γ-tubulin MAP2a BRCA1 
Δ-tubulin MAP2b Survivin 
ε-tubulin MAP2c pVHL 
 MAP4 Eg5 
 MAP7 MAP215/TOG 
Table 1. Various tubulin and microtubule associated proteins. Δ- and ε-tubulin are also 
involved in cetrosome formation. MAP-proteins participate both in microtubule 
polymerization and depolymerization, and include some motor proteins as well.  
 
Microtubules have become popular targets for cancer therapy. Microtubule-targeting 
agents, such as paclitaxel, colchicine and vinca alkaloids are used in cancer treatment. 
Their effectiveness is based on their ability to effect microtubule dynamics. This has 
an impact on cancer cells, which are constantly dividing, and require a functional 
mitotic spindle. These microtubule-disrupting agents hinder cancer cells from 
dividing. However, cancer cells have developed multiple ways of evading these 
microtubule-disrupting agents. They become resistant to these drugs for example by 
over-expressing mdr1 gene that encodes for an efflux pump that keeps the drugs out 
of the cells. Alternative strategies for cancer cells to avoid death by these drugs are 
altered tubulin gene expression, altered interaction of the drugs with the microtubules 
or inadequate induction of apoptotic signaling. New and better microtubule-disrupting 
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agents are sought, and the conventional drugs (colcisin and paclitaxel) have also 
unwanted side effects such as neurotoxicity (due to high amount of microtubules in 
neurons) (Dumontet & Sikic, 1999). Another emerging field of research focuses on 
MAPs as possible cancer therapy targets (Bhat & Setaluri, 2007).  
 
3.3 Intermediate filaments 
Intermediate filaments are ropelike protein fibers that tolerate stretching and bending. 
They constitute the internal three-dimensional structure of the cell and the protective 
cage around the nucleus, the nuclear envelope. They also keep epithelial cell sheets 
together, help neuronal cells to extend axons and form tough appendages, such as hair 
and nails. Intermediate filaments are made up of filamentous proteins. So far, 67 
genes encoding intermediate filament proteins have been identified, which makes this 
gene family one of the largest in the human genome (Table 2). Many members of the 
intermediate filament protein family are expressed abundantly and differentially in 
complex patterns during embryonic development and in the terminally differentiated 
cell types, making intermediate filaments cytoskeletal ‘identity cards’. Intermediate 
filaments also provide each cell type with unique cytoskeletal architecture. One of the 
most well known families of intermediate filament proteins is the keratin-family, 
which form our skin, nails and hair.  
The individual proteins of intermediate filaments are elongated molecules with an 
extended α-helical domain that forms a parallel coiled-coil with another molecule. 
This dimer then associates with another dimer to form a tetramer. The assembled 
intermediate filament lacks the polarity that is characteristic of microtubules and 
microfilaments (Chang & Goldman, 2004, Helfand et al, 2004).  
 
Subtype I and II Subtype III Subtype IV Subtype V Subtype VI 








 Peripherin Synemin α/β   
 Vimentin Syncoilin   
Table 2. Intermediate filament subtypes (http://www.interfil.org/index.php) 
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All three cytoskeletal systems are interconnected via proteins that are able to bind the 
different cytoskeletal proteins. For instance, during cell division and cell migration, 
microtubules and actin cytoskeleton need to perform their tasks in an orderly manner. 
However, this crosstalk is not yet completely understood, and the mechanisms by 
which these cross-linking proteins function to connect these two systems are still 
somewhat unclear. Small GTPases, such as Rac, Rho and Cdc42 have been shown to 
influence both networks, but they do this by modulating signaling networks rather 
than binding actin or tubulin directly (Kodama et al, 2004). 
 
4. FERM-domain proteins 
Ezrin-radixin-moesin-proteins (ERM) form a family of closely related intracellular 
proteins that crosslink actin filaments to the plasma membrane, and participate in 
signal-transduction pathways. They regulate the structure and function of specific 
domains of the cell cortex. They are widely expressed, membrane-associated proteins, 
that are highly homologous and they also share a common feature, the band four-
point-one ezrin-radixin-moesin homology-domain (FERM-domain) that makes them 
members of the band 4.1 protein superfamily. The Neurofibromatosis 2 tumor 
suppressor merlin (also known as schwannomin) contains the FERM-domain and is 
highly homologous to the ERM-proteins from its FERM-domain (reviewed in 
Bretscher et al 2002).  
 
4.1 The FERM-domain 
The FERM-domain is a widespread protein module of approximately 300 amino acids 
that is involved in localizing proteins to the plasma membrane. The FERM-domain 
was originally identified in the band 4.1 protein that was isolated from human 
erythrocytes (Leto & Marchesi, 1984). The 30-kDa FERM domain of protein band 4.1 
is a cysteine-rich, basic globular module (Chishti et al, 1998). Most FERM-domain 
proteins function as conformationally regulated membrane:cytoskeleton cross-linkers 
in actin-rich cell surface structures (reviewed in Bretscher et al 2002).  
The structure of FERM-domain has been resolved by protein crystallography 
(Pearson et al, 2000). This globular domain consists of three sub-domains (F1, F2 and 
F3) that are arranged in a cloverleaf-like fashion. Even though there seems to be no 
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Figure 5. Domain structure of merlin in comparison to the other ERM-proteins. ERM-
proteins consist of the amino-terminal FERM-domain (three sub-domains have been marked 
F1, F2 and F3), the central α-helical domain and the C-terminal domain (C-ERMAD, C-
terminal ERM association domain. Percentages indicate the amino-acid sequence similarity.  
 
evident sequence conservation, all three sub-domains are homologous to protein 
domains that have been described before: the F1-domain resembles ubiquitin, F2 
resembles Acyl-CoA binding protein and F3 shows structural homology to the 
phospho-tyrosine binding (PTB), pleckstrin-homology and Enabled/VASP-1 (EVH1) 
domains (Pearson et al, 2000). The FERM-domain binds peptide and lipid ligands in 
signaling and cytoskeletal proteins. The FERM-domains of ERM-proteins and their 
homologues from different species show remarkable sequence conservation. ERM-
proteins show 74-82% identity between their FERM-domains and also merlin 
displays 60% identity to ezrin’s FERM-domain. This indicates that the structure has 
been exceptionally well conserved (Bretscher et al, 2002).  
 
4.2 ERM-proteins and merlin 
Ezrin, radixin and moesin, together with tumor suppressor merlin comprise one class 
of the band 4.1 superfamily (Fig. 5) (Rouleau et al, 1993, Sato et al, 1992, Trofatter et 
al, 1993). They link various membrane proteins to the actin cytoskeleton and 
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participate in a wide range of signaling pathways, such as the Ras-pathway. They also 
regulate the structure and function of specific domains of the cell cortex. Ezrin was 
the first family member that was identified as a component of actin rich membrane 
structures, such as microvilli and membrane ruffles (Bretscher, 1983, Pakkanen et al, 
1987). Radixin was isolated from hepatic adherens junctions (Tsukita et al, 1989), and 
was shown to localize to microvilli (Amieva et al, 1994, Henry et al, 1995) and the 
cleavage furrow (Sato et al, 1991) in several cell types. Moesin is also enriched in 
actin rich membrane structures (Amieva & Furthmayr, 1995, Franck et al, 1993), 
although it was originally discovered for its ability to bind heparin (Lankes & 
Furthmayr, 1991).  
 
ERM-proteins link F-actin to membrane proteins in a regulated fashion (Tsukita et al, 
1994). They contain an F-actin binding site in their C-terminal part, however, this 
binding site is masked in the dormant molecule (Nakamura et al, 1999, Pestonjamasp 
et al, 1995, Turunen et al, 1994). Regulated attachment of membrane proteins to actin 
is important in many cellular functions, such as determination of cell shape, polarity, 
cell adhesion, motility and integration of signaling pathways with membrane 
transport.  
Merlin was found in 1993 when the Neurofibromatosis 2 (NF2) tumor suppressor 
gene was identified (Rouleau et al, 1993, Trofatter et al, 1993). The subsequent 
protein product joined the family of ERM-proteins as it showed high similarity 
structurally and functionally to ERM-proteins, and hence, the protein was named 
merlin for moesin-ezrin-radixin-like protein (Trofatter et al, 1993), or schwannomin 
(Rouleau et al, 1993), describing its suppressor role in schwannoma formation. Like 
the other ERM-proteins, also merlin links the plasma membrane to the cytoskeleton 
and participates in conveying signals from the plasma membrane to the cell interior. 
However, merlin functions as a tumor suppressor. Despite the apparent sequence 
homology between merlin and ERM-proteins, merlin seems to perform a defined set 
of functions that no other protein is able to compensate, whereas the ERM-proteins 
seem to have overlapping functions (Takeuchi et al, 1994). Merlin knock-out in mice 
is embryonically lethal (McClatchey et al, 1997) whereas ezrin knock-out mice are 
viable although they have problems in epithelial organization in the developing 
intestine (Saotome et al, 2004). Radixin knock-out mice are normal at birth but 
develop mild liver injuries at the age of 8 weeks (Kikuchi et al, 2002), and moesin 
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knock-out mice appear to be normal, showing no change in ezrin or radixin 
expression (Doi et al, 1999).  
 
Although the FERM-domains in all four proteins are quite similar (60% homology 
between human ERMs and merlin) (Pearson et al, 2000), there are regions in merlin 
that are conserved between mammalian and Drosophila merlin but that are distinct 
from the ERM-proteins. The FERM-domain structure shows that most divergent 
residues between merlin and the ERM-proteins are found clustered at the surface of 
the FERM-domain where these exposed residues might serve as sites for effector 
binding or regulatory interactions (reviewed in Bretscher et al., 2002) (Bretscher et al, 
2002). Another conserved feature between mammalian and Drosophila merlin is the 
‘blue box’ domain, a perfectly conserved seven-amino-acid stretch of basic residues 
(aa 177-183) (LaJeunesse et al, 1998) which has been shown to be essential for 
merlin’s functions both in flies (LaJeunesse et al, 1998) and humans (Stokowski & 
Cox, 2000).  
 
ERM-proteins and merlin are capable of forming homo- and heterotypic associations 
with the other ERM-proteins, thus forming dimers and oligomers (Berryman et al, 
1995, Gary & Bretscher, 1993, Gronholm et al, 1999). The accessibility of merlin and 
ERM-proteins is regulated by intramolecular association between their N- and the C-
terminal domains (Fig. 6). When the FERM-domain binds the C-terminal domain it 
forms a ‘closed’ protein molecule that masks many of the binding sites and inhibits 
interactions with some of the binding partners as well as the homo- and 
heterodimerization (Grönholm et al, 1999). Activation is needed to ‘open’ the 
molecule and for the separation of the two domains. This activation takes place in 
response to various cellular signals, such as phosphorylation and binding of lipids. 
Phosphorylation of ezrin, radixin and moesin on a conserved threonine (T558 in 
moesin, T567 in ezrin and T564 in radixin) and binding of the lipid, 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2, or PIP2), has been shown to 
open and ‘activate’ the molecule (Gautreau et al, 2000, Hirao et al, 1996, Nakamura 
et al, 1995, Nakamura et al, 1999). Several kinases phosphorylate the conserved 
threonine: Rho kinase (Matsui et al, 1998, Tran Quang et al, 2000), protein kinase Cα 
(PKCα) (Ng et al, 2001), protein kinase Cθ (PKCθ) (Pietromonaco et al, 1998, 
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Simons et al, 1998) and phosphatidylinositol-4-phosphate-5-kinase (Matsui et al, 
1999). 
ERM-proteins anchor F-actin to the plasma membrane by binding transmembrane 
receptors, such as hyaluronan receptor CD44 (Tsukita et al, 1994) and intracellular 
adhesion molecules (ICAM’s) (Heiska et al, 1998). ERM-proteins bind CD44 only in 
the presence of PIP2 (Hirao et al, 1996) and further studies have revealed that PIP2 is 






Figure 6. Model of conformational regulation of merlin and ERM-proteins. Merlin’s 
FERM-domain (black) forms a clover-leaf like structure which is able to bind its C-terminus 
(grey) to form a closed conformation (right). Upon phosphorylation (P) molecule is activated 
and conformation becomes opened (left).  
 
5. Neurofibromatosis 2 (NF2)  
NF2 disease is an autosomal dominant, needing only one affected allele from either 
parent to inherit the disease manifested as multiple tumors of the central nervous 
system, in particular schwannomas and meningiomas. Biallelic inactivation of the 
NF2 gene is also commonly found in sporadically occurring schwannomas and 
meningiomas (Lomas et al, 2005, Ruttledge et al, 1994, Stemmer-Rachamimov et al, 
1997b). In addition, inactivation of the NF2 gene has been reported to occur in 
asbestos exposed mesotheliomas of the lung (Bianchi et al, 1995, Sekido et al, 1995), 
sporadic thyroid carcinomas (Sheikh et al, 2004), hepatocellular carcinomas and in 
perineurial cell tumors (Lasota et al, 2001, Pineau et al, 2003, Sheikh et al, 2004).  
 
The incidence of the NF2 disease is low, 1 in 35.000-70.000, with high penetrance 
(>95%) (Antinheimo et al, 2000, Evans et al, 1992). The most typical hallmark of the 
disease is the formation of bilateral schwannomas (Schwann cell tumors) around the 
vestibular branches of the eight cranial nerves. In addition, some patients develop 
multiple schwannomas associated with other cranial nerves, meningiomas (tumors 
 P 
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derived from meningeal cells), astrocytomas (derived from astrocytes) and intraspinal 
ependymomas (derived from ependymal cells) (reviewed in Baser et al. 2003). The 
tumors in NF2 are usually slowly growing and benign. They respond poorly to 
radiation and are difficult to operate due to their location and therefore, the morbidity 
among NF2 patients is high. Vestibular schwannoma growth rates among young 
patients are generally high and extremely variable even among members of the same 
family with the same age (Mautner et al, 2002). This indicates that other factors than 
simply the mutation in the NF2 gene affect the outcome of the disease. Genotype-
phenotype correlations have been examined in NF2. Patients with nonsense or frame-
shift mutations usually have a more severe disease than patients with missense 
mutations, in-frame deletions or large deletions (Baser et al, 2002, Baser et al, 2005). 
It has been shown that all schwannomas lack functional NF2 protein, for 
meningiomas, the case is not as simple. All NF2 related meningiomas lack functional 
NF2 gene, but in sporadic meningiomas only 50% lack functional NF2 gene, 
suggesting that additional factors influence the formation of sporadic meningiomas. In 
addition, NF2 status strongly depends on the meningiomas subtype, depending on the 
subtype, 20-80% of meningiomas lack functional NF2 gene (Hanemann & Evans, 
2006, Riemenschneider et al, 2006). 
The NF2 gene is located on chromosome 22q12 (Rouleau et al, 1993, Trofatter et al, 
1993) and encodes the merlin protein. It is composed of 17 exons, with two 
alternatively spliced major isoforms, I and II (Hara et al, 1994). Isoform I lacks exon 
16, whereas isoform II contains exon 16 but lacks exon 17, thus replacing 16 C-
terminal residues with 11 new residues. In addition, more alternatively spliced 
isoforms have been reported (Hara et al, 1994, Schmucker et al, 1999), however, 
these isoforms are not widely expressed and at least some of these isoforms are 
degraded by the ubiquitin-proteasome pathway (Gautreau et al, 2002).  
 
5.1 Merlin 
During mouse embryonic development, high amount of merlin is detected in extra-
embryonic tissues. Merlin is also expressed in nervous and skeletal systems and in the 
heart of mice and human. In adult tissues, merlin is widely expressed but expression 
levels are low. Merlin mRNA is found in heart, brain, spleen, lung, liver, skeletal 
muscle and kidney. Significant amounts of the protein are expressed in Schwann 
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cells, meningeal cells, lens and nerve cells whereas smaller amounts of the protein are 
expressed in lung, intestine, muscle, spleen, kidney and erythrocytes (Claudio et al, 
1995, Gronholm et al, 2005, Hara et al, 1994, Huynh et al, 1996, Jindal et al, 2006, 
Rouleau et al, 1993).  
Studies of merlin localization in cells have been complicated by the low amount of 
the endogenous protein. Therefore, many of the studies were done by expressing 
exogenous protein, which may not reflect the true localization of the endogenous 
protein. However, in cultured mammalian cells, both endogenous and over-expressed 
merlin are localized to actin-rich structures at the membrane and to cell:cell contacts, 
perhaps reflecting merlin’s role in mediating contact dependent inhibition of growth 
(Gonzalez-Agosti et al, 1996, Lallemand et al, 2003, Sainio et al, 1997). Merlin is 
also shown to localize diffusely to the cytoplasm and to punctuate structures. These 
are thought to represent localization to intracellular vesicles or to lipid rafts 
(McCartney & Fehon, 1996, Stickney et al, 2004). In the central nervous system 
(CNS) merlin is expressed in coarse cytoplasmic granules in glia and neurons and in 
synaptic junctions in cultured polarized neurons (Grönholm et al, 2005, Stemmer-
Rachamimov et al, 1997a).  
 
5.2 Model organisms 
Merlin orthologs have been found in a wide variety of species (Drosophila 
melanogaster, Anopheles gambiae, Apis mellifera, Caernohabditis elegans, Xenopus 
laevis, Danio rerio, Oryzias latipes, Gallus gallus, Mus musculus, Homo sapiens) 
(Golovnina et al, 2005), but not in yeast (Saccharomyces cerevisiae).  
Mouse and human merlin show 98% sequence identity. Three different Nf2 mutant 
mice have been engineered that have a homozygous germ-line mutations of the Nf2 
gene. These mice are not viable, due to embryonic death at early stage of 
development. Embryos fail to initiate gastrulation, and to form extra-embryonic 
structures (Giovannini et al, 2000, McClatchey et al, 1997). Merlin function is also 
required during D. melanogaster development and lack of merlin leads to 
overproliferation  of cells of D. melanogaster (Fehon et al, 1997, LaJeunesse et al, 
1998). Heterozygous Nf2 mutant mice develop bone tumors that have lost the Nf2 
wild type allele (Giovannini et al, 2000, McClatchey et al, 1997), but do not 
spontaneously develop tumors that are classical for the NF2 disease in humans 
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(reviewed in McClatchey and Giovannini 2005) (McClatchey & Giovannini, 2005). 
However, inactivation of both Nf2 alleles in only Schwann cells produces mice with 
features found in NF2 patients; these mice develop Schwann cell hyperplasia, 
Schwann cell tumors and cerebral calcifications, but not meningiomas (Giovannini et 
al, 2000). However, Nf2 mice with targeted deletion of the Nf2 gene in 
leptomeningeal cells display meningioma formation (Kalamarides et al, 2002). 
 
5.3 Schwann cells 
Schwann cells express ERM proteins and merlin, but only the absence of merlin 
results in NF2-related schwannomas. This implicates a special role for merlin in this 
cell type. Schwann cells are a subtype of neuroglia, which provide insulation to 
neurons by forming myelin sheaths around axons (Fig. 7). Schwann cells provide 
myelin for the axons of the peripheral nervous system, whereas oligodendrocytes 
myelinate axons of the central nervous system. Myelination increases the rate of 
conduction of the action potential dramatically, and thus reduces the necessity to 
increase the axon diameter. The myelin sheath is interrupted at regular intervals by 
the nodes of Ranvier, where sodium channels of the axon are concentrated. 
Schwannoma cells that are isolated from the NF2 patients show cytoskeletal changes 
in their actin and intermediate filament cytoskeletons when compared to normal 
Schwann cells (Bashour et al, 2002, Pelton et al, 1998, Rosenbaum et al, 1998, 
Utermark et al, 2005).   
 
Figure 7. Mouse primary Schwann cells. Stained for α-tubulin, 1000x magnification. 
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6. Functions and regulation of merlin 
Already early experiments with merlin showed its potential as a tumor suppressor. 
Over-expressed wild type merlin inhibits cell proliferation in NIH3T3 (Lutchman & 
Rouleau, 1995) and schwannoma cells (Sherman et al, 1997), and can reverse the 
Ras-induced malignant phenotype in NIH3T3 cells (Tikoo et al, 1994). Merlin also 
negatively regulates cyclin D1 levels, a major contributor of cell cycle progression in 
G1 (Xiao et al, 2005). In addition, merlin enhances the stability of p53, by degrading 
a p53-inhibitor mouse double minute 2 (Mdm2) (Kim et al, 2004). Heterozygous Nf2 
mice develop a wide range of tumors (Giovannini et al, 2000), and cultured cells 
lacking merlin fail to undergo contact dependent growth arrest (Lallemand et al, 
2003). Due to merlin’s localization to the areas of the plasma membrane:cytoskeleton 
interface, it has been considered a unique type of tumor suppressor. Therefore, merlin 
has been studied mainly in this cellular compartment.  
 
6.1 Interactions with the cytoskeleton and the plasma membrane 
Merlin binds F-actin directly with its FERM-domain, but lacks the C-terminal F-actin 
binding site found in other ERM-proteins (Brault et al, 2001, James et al, 2001, Xu & 
Gutmann, 1998). Merlin can also bind actin indirectly via its binding partners β-
spectrin/fodrin (Scoles et al, 1998), paxillin (Fernandez-Valle et al, 2002), other 
ERM-proteins (Grönholm et al, 1999, Meng et al, 2000) and neural Wiskott-Aldrich 
syndrome protein (N-WASP) (Manchanda et al, 2005). Merlin’s interaction with N-
WASP has been shown to regulate actin dynamics in vitro, since this interaction 
inhibits actin polymerization (Manchanda et al, 2005). In addition, merlin stabilizes 
actin polymers in vitro by directly binding to actin filaments through a lateral 
association (James et al, 2001). These two functions appear to be independent from 
each other (Manchanda et al, 2005).  
Merlin can anchor actin fibers to the plasma membrane by binding to transmembrane 
receptors, such as CD44 (Morrison et al, 2001, Sainio et al, 1997), layilin (Bono et al, 
2005), β1-integrin (Obremski et al, 1998), ErbB2 (Fernandez-Valle et al, 2002) and 
paranodin (Denisenko-Nehrbass et al, 2003). Additionally it can bind membrane 
proteins indirectly by binding PDZ-domain containing protein NHE regulatory factor 
1/ERM-binding phosphoprotein 50 (NHERF1/EBP50) (Murthy et al, 1998). 
NHERF1/EBP50 can link merlin to other membrane proteins, such as platelet-derived 
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growth factor receptors (PDGF) (Voltz et al, 2001). Through its interaction with 
transmembrane receptors merlin is thought to convey signals from the extracellular 
matrix inside the cell. For example its interaction with hyaluronic acid receptor CD44 
is regulated by cell density and by the degree of merlin phosphorylation (Morrison et 
al, 2001). It is thought that merlin together with CD44 forms a molecular switch that 
conveys signals of growth arrest and proliferation (Morrison et al, 2001).  
Recently, merlin has been linked to growth factor receptor recycling and endocytic 
trafficking (reviewed in McClatchey and Giovannini 2005). The first clue in this 
direction came from studies where merlin was shown to interact with hepatocyte 
growth factor receptor substrate (Hrs), which is an important controller of lysosomal 
trafficking of membrane receptors (Scoles et al, 2000), and regulates receptor tyrosine 
kinase trafficking to the degradation pathway (Lloyd et al, 2002). Merlin also 
interacts with other proteins with roles in growth factor receptor signaling (Table 3.). 
These include growth factor receptor-bound protein 2 (Grb2), magicin/MED28 
(Wiederhold et al, 2004) and NHERF-1/EBP50 (Murthy et al, 1998). Merlin also 
inhibits platelet derived growth factor receptor (PDGFR) degradation (Fraenzer et al, 
2003). It localizes to vesicular structures in both, mammalian cells and Drosophila 
(Maitra et al, 2006, Scoles et al, 2000). Recently merlin was shown to regulate 
endothelial growth factor receptor (EGFR) recycling and turnover in Drosophila 
(Maitra et al, 2006) and in mouse embryonic fibroblasts (Curto et al, 2007), and to 
have a role in ErbB2 receptor recycling in Schwann cells (Lallemand et al., personal 
communication).  
 
Merlin’s binding partners: 
cytoskeletal: transmembrane: receptor recycling: signaling pathways:  
tubulin CD44 Hrs RIβ RalGDS 
ERM laylin Grb2 PAK magicin 
F-actin β1-integrin NHERF1/EBP50 PIKE-L TRBP 
N-WASP ErbB2 ErbB2 HEI10 syntenin 
βII-spectrin paranodin  Rho-GDI NGB 
paxillin   MYPT-1 MAP 
   eIF3c  
Table 3. Merlin’s known binding partners classified according to their function. 
(Transactivation-responsive RNA-binding protein (TRBP) (Lee et al, 2004b, Lee et al, 
2006a), syntenin (Jannatipour et al, 2001), merlin-associating protein (MAP) (Lee et al, 
2004a)), eukaryotic initiating factor subunit 3c (eIF3c) (Scoles et al, 2006). 
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6.2 Phosphorylation and conformational regulation  
Merlin undergoes analogous conformational regulation between its N- and C-terminus 
as the ERM proteins (Grönholm et al, 1999, Gutmann et al, 1999, Gutmann et al, 
2001, Huang et al, 1998, Meng et al, 2000, Neill & Crompton, 2001, Rong et al, 
2004a), but the activation mechanism for merlin is still unclear. The threonine (T576) 
involved in conformational activation of ERM-proteins is conserved in merlin, but 
this residue has not been shown to play any role in its conformational activation. 
However, another C-terminal residue, not found in the other ERM-proteins, serine 
518 (S518), is phosphorylated in merlin and appears, at least to some extent, to 
regulate merlin’s conformation. Phosphorylation of S518 inactivates the protein’s 
tumor suppressor mechanism and promotes growth (Morrison et al, 2001, Shaw et al, 
2001). Two kinases have been shown to phosphorylate merlin at S518, p21 activated 
kinase (PAK) 1 and 2 (Kissil et al, 2002, Shaw et al, 2001), and cAMP activated PKA 
(Alfthan et al, 2004). PAKs 1-3 are downstream effectors of Rho GTPases Rac and 
Cdc42 (see below). PAKs mediate signals of cytoskeletal reorganization, cell motility 
and transcriptional activation (reviewed in Kumar et al., 2006). Merlin is not only 
phosphorylated by PAK, but is also able to modulate PAK, by binding and inhibiting 
PAK activity, thus forming a negative feedback loop. Binding is enhanced by cell 
confluency (Hirokawa et al, 2004, Kissil et al, 2003) perhaps indicating that it is the 
dephosphorylated merlin that binds PAK.  
PAK and PKA act independently from each other since PKA phosphorylates merlin 
in cells where PAK activity is suppressed (Alfthan et al, 2004). cAMP regulates a 
wide variety of cellular processes and it has been shown that cAMP driven activation 
of PKA leads to proliferation in Schwann cells (Kim et al, 1997), and is required for 
myelin formation (Howe & McCarthy, 2000). Merlin also binds the PKA regulatory 
subunit RIβ and may work as a protein kinase A-anchoring protein (AKAP) in 
neurons (Grönholm et al, 2003). An additional kinase indicated in merlin 
phosphorylation is the Slik-kinase, found to affect merlin phosphorylation in 
Drosophila. However, it is still unclear whether this phosphorylation is direct 
(Hughes & Fehon, 2006). 
A recent paper describes myosin phosphatase MYPT-1-PP1δ as the first phosphatase 
that dephosphorylates merlin at S518 (Jin et al, 2006). Inhibiting MYPT-1-PP1δ with 
a 17-kDa protein kinase C potentiated inhibitor (CPI-17), results in merlin 
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phosphorylation, Rac activation and transformation (Jin et al, 2006), indicating a 
crucial role for merlin dephosphorylation in growth suppression.  
 
6.2.1 Rho GTPases 
Rho GTPases regulate cell polarity and motility and they play a major role in actin 
cytoskeleton remodeling. They activate actin nucleators, which in turn induce 
different types of actin organization. The best studied members of this family are Rho, 
Rac and Cdc42, of which Rac and Cdc42 induce plasma membrane protrusions, such 
as lamellipodia and filopodia and Rho regulates vesicle trafficking and stress fiber 
formation (reviewed in Ridley 2006). Rho GTPases bind GTP and GDP, and they 
have intrinsic GTPase activity. In their GTP-bound state they are able to activate 
downstream target proteins. Their activity is regulated by guanine nucleotide 
exchange factors (GEF’s), which result in the release of GDP, thus allowing GTP to 
bind (Ridley, 2006). 
Ras is also a small GTPase protein and its activation takes place upstream of Rac 
activation (Scita et al, 1999). Rac1 activation leads to merlin phosphorylation, 
probably through PAK (Kissil et al, 2002, Shaw et al, 2001, Xiao et al, 2002). 
However, merlin in turn inhibits Ras and Rac activation by uncoupling them from 
growth factor signals (Morrison et al, 2007), not by direct binding but by 
counteracting ERM-dependent Ras and Rac activation (Morrison et al, 2007). In 
schwannomas, lack of merlin leads to increased Rac activity, and to the interruption 
of the neuron-Schwann cell alignment, a process which needs Rac regulation (Nakai 
et al, 2006). Merlin has also been shown to interact with a Rho-guanine dissociation 
inhibitor (Rho-GDI) (Maeda et al, 1999), which inhibits nucleotide exchange of the 
Rho family members, and with Ral guanine nucleotide dissociation stimulator 
(RalGDS) (Ryu et al, 2005). Thus, merlin could anchor these nucleotide exchange 
factors to plasma membrane thereby affecting Ras and Rac downstream signaling 
(McClatchey & Giovannini, 2005, Morrison et al, 2007). Recently, merlin was also 
shown to interact with a novel tumor suppressor that has intrinsic GTPase activity, 
NF2-associated GTP binding protein (NGB), which suppresses growth in a merlin-
dependent fashion (Lee et al, 2007). NGB is a GTP-binding protein conserved from 
yeast to mammals, and it suppresses growth co-operatively with merlin by reducing 
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Cyclin D1 levels and increases merlin turnover by reducing its ubiquitinylation (Lee 
et al, 2007).  
 
6.3 Merlin regulation of signaling pathways 
Merlin is implicated in the regulation of several proteins that affect cell-signaling 
pathways (Fig. 8). Focal adhesion kinase (FAK) is up-regulated in many cancers and 
promotes cell migration and invasion. Down-regulation of merlin in mouse embryonic 
fibroblasts leads to increased spreading and invasion, whereas merlin expression leads 
to increased FAK phosphorylation. This, in turn, disrupts its interaction with the 
regulatory subunit of PI3K, p85 and Src (Poulikakos et al, 2006), an interaction 
required for cell migration (Shen & Guan, 2001).  
 
Recently, merlin, together with tumor suppressor protein Expanded, a related FERM-
domain protein, were found to negatively regulate the Hippo signaling pathway in D. 
melanogaster (Hamaratoglu et al, 2006). The Hippo signaling pathway consists of a 
kinase cascade that ultimately leads to the inhibition of a transcriptional co-activator 
Yorkie, which normally controls cell growth, survival and proliferation (reviewed in 
Edgar 2006). Merlin and Expanded activate Hippo/Salvador kinase in response to a 
yet unidentified signal from a membrane receptor. The activated kinase complex then 
phosphorylates its downstream target, the Warts/Mats kinase complex, which in turn 
phosphorylates Yorkie. In its phosphorylated state Yorkie is inactive and inhibits 
transcription (Edgar, 2006, Hamaratoglu et al, 2006). This signaling cascade forms a 
negative feedback loop, as Yorkie also regulates transcription of merlin and Expanded 
(Hamaratoglu et al, 2006). All components of this pathway are conserved in humans, 
but so far it is only the lack of merlin that causes tumors. 
  
Merlin has also been shown to interact with a novel cytoskeletal protein, magicin 
(merlin and Grb2 interacting cytoskeletal protein) (Wiederhold et al, 2004), also 
known as MED28 (Sato et al, 2004). Merlin forms a complex with magicin and Grb2, 
that can regulate receptor tyrosine kinase and Ras signaling (Wiederhold et al, 2004). 
Merlin also interacts with the PI3-kinase enhancer (PIKE-L), which is a brain specific 
GTPase that binds PI3-kinase and increases its lipid kinase activity. By binding PIKE-
L merlin inhibits the PIKE-L:PI3-kinase interaction, thus inhibiting the PI3-kinase. 
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Interestingly, knocking down PIKE-L abolishes merlin’s tumor suppressor activity in
RT4 rat schwannoma cells (Rong et al, 2004b).
Lack of merlin leads to upregulation of both phosphorylated extracellular-signal
regulated kinase (ERK) (Chadee et al, 2006, Jung et al, 2005, Lim et al, 2006,
Rangwala et al, 2005), c-Jun N-terminal kinase (JNK) and PAK (Chadee et al, 2006,
Kaempchen et al, 2003). Upon phosphorylation ERK translocates into the nucleus
where it activates downstream targets, which ultimately leads to cell growth and
proliferation. Activation of the Rac1-PAK-JNK-pathway also leads to transcriptional
activation and cell proliferation.
Figure 8. Merlin signaling pathways. Extracellular growth-factors bind to growth-factor
receptors. This results in various downstream signaling cascades, that merlin is able to
regulateor participate. These signaling cascades ultimately lead to the activation or repression
of transcription. (GPCR (G-protein coupled receptor) conveys signals that lead to activation
of adenylyl cyclase and increase in cAMP. It also activates phospholipase C, Src and PI3K,
which then leads to Raf, Ras and Akt activation (not shown)). These molecules represent only
a fraction of all the proteins that take part and regulate these processes.
Thus, merlin’s role in cell proliferation includes participation in several signaling
pathways that merlin is able to regulate, perhaps by affecting phosphorylation or
interactions of signaling cascade partners at the cell membrane. Despite all the
studies, the precise mechanism of action how merlin performs its specific functions in
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a spatio-temporal manner and in different tissues remains unclear. Clarifying these 
mechanisms would be of great importance to cancer biology as this knowledge may 
translate into therapeutic opportunities in the treatment of NF2 patients. 
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AIMS OF THE STUDY 
 
At the beginning of this study, merlin was considered as a unique type of tumor 
suppressor, which performs its function at the membrane. However, preliminary 
observations of merlin’s localization during different stages of the cell cycle led us to 
challenge this view. Therefore I set out to study what additional functions merlin 
could have, and what purpose would these novel functions serve. The specific aims of 
this study were:  
 
1) To study merlin’s localization during different stages of the cell cycle and to 
determine the mechanisms and consequences of merlin’s nucleo-cytoplasmic 
shuttling.  
2) To identify interaction partners for merlin in the nucleus, and to study the 
functional relevance of these interactions.  
3) To study merlin’s association with the microtubule cytoskeleton, and to 
examine merlin’s role in the regulation of the microtubule cytoskeleton in 
primary mouse Schwann cells and other relevant cell types.  
4) To further study the role of phosphorylation in the regulation of merlin, and 
more specifically, to analyze the consequences of N-terminal phosphorylation 
of merlin by PKA.  
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MATERIALS AND METHODS 
The materials and methods used in this study are listed below, and are described in 
detail in the original publications, which are referred to here by using their Roman 
numerals.   
 
Antibodies and probes used in this study:  
NAME DESCRIPTION REFERENCE USED IN  
 
A-19 (sc-331) Merlin pAb  Santa Cruz Biotechnology I, II, III, 
IV 
C-18 (sc-332) Merlin pAb  Santa Cruz Biotechnology  
1398 NF2 Merlin pAb (den Bakker et al, 1995a) I 
schwannomin Merlin pAb  (Lutchman & Rouleau, 1995) I 
HM2175 Merlin pS518 pAb (Kissil et al, 2002) I 
1C4 Merlin mAb (Gonzalez-Agosti et al, 1996) II 
KF10 Merlin mAb (den Bakker et al, 1995b) I, II 
α-tubulin α-tubulin mAb Sigma-Aldrich III, IV 
β-tubulin β-tubulin mAb Sigma-Aldrich III 
N356 mAb α-tubulin Amesham Pharmacia 
Biotech.  
I, II 
Acetyl-tubulin Acetylated tubulin 
mAb 
Sigma-Aldrich III 
α-HEI10 HEI10 pAb (Toby et al, 2003) II 
α-porin α-porin mAb Invitrogen-Molecular Probes I 
ERK2 ERK2 pAb Santa Cruz Biotechnology  
p75 p75 mAb (Huber & Chao, 1995) III 
MAT-1 fl-309 Mat1 pAb Santa Cruz Biotechnology I 
Hermes  CD44 mAb (Jalkanen et al, 1987) I 
α-Myc Myc mAb Covance Research Products  I 
α-HA HA mAb Roche I 
GST GST pAb goat GE Healthcare  
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X63 mAb, negative control ATCC I 
TO-PRO 3 Nucleic acid stain Invitrogen-Molecular Probes I, II 
phalloidin Oregon green and 
rhodamine conjugated 
Invitrogen-Molecular Probes I, IV 
    
 
Cell lines used in this study:  
CELL LINE DESCRIPTION SOURCE USED IN 
 
U2OS Human osteosarcoma ATCC I, II 
U251MG Human glioma Japan cell line collection I, II, III 
293HEK Human kidney epithelial  ATCC I, II 
293A Human kidney epithelial Stratagene III, IV 
RT4 Rat schwannoma (Morrison et al, 2001) II 
RT4-5-4 Rat schwannoma (Morrison et al, 2001) II 
Schwann Human primary (Hanemann et al, 1998) II 
Schwannoma Human primary (Rosenbaum et al, 1998) II 
Schwann Mouse primary (Manent et al, 2003) III, IV 
COS-7 Monkey kidney ATCC IV 
Nf2 -/- MEFs Mouse embryonic 
fibroblasts 
(Giovannini et al, 2000) IV 
 
Expression vectors used in this study:  





Constitutively active PAK2 with myc-
HA tag 






Dominant negative PAK2 with myc tag (Alfthan et al, 
2004) 
I 
pcDNA3 Mammalian expression vector 
containing various merlin (aa): 1-595, 
Invitrogen I, II, IV 
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1-590, 1-547, 1-537, 1-569, 1-587, 1-
314, 492-595, 1-547/ins307 and HEI10 
constructs 
pYESTrp2 Yeast two hybrid prey vector with 
merlin (aa) 1-547 construct with 
transposon mutations 
Invitrogen II 
pGEX4T-1 Bacterial expression vector containing 
several merlin (aa): 1-314, 314-595, 
492-595, 492-595 S518A, 1-100, 492-
547, ezrin 1-585  and HEI10: 1-277, 
46-277,  constructs 
Amersham 
Biosciences 
II, III, IV 
JG4-5 Yeast two hybrid prey vector 
containing various HEI10 constructs 
(aa): 1-277, 1-143, 1-200, 40-250, 116-
277, 175-277 
(Gyuris et al, 
1993) 
II, IV 
EG202 Yeast two hybrid bait vector containing 
various merlin constructs (aa): 1-595, 
1-595 S518A, 1-595 S518D, 1-595 
T576A, 1-595 T576D, 1-590, 1-339, 1-
546, 252-595, 252-595 A468P, 252-
595 L316W, 252-595 L316T, 339-595, 
306-478, 492-595 and ezrin (aa): 1-
585, 1-309, 278-585 
(Gyuris et al, 
1993) 
II, IV 
pEGFP-Tub Mammalian expression vector 
containing tubulin-GFP 
Invitrogen III 
pBaculoGold Baculovirus vestor containing merlin 




pShuttle Shuttle vector for adenovirus vector 
pAdEasy containing merlin isoform 1, 
merlin isoform 1 S10A/S10D 
Stratagene III, IV 
pAdEasy Adenovirus vector with merlin isoform 
1, isoform 1 S10A/S10D 
Stratagene III, IV 
pENTR3C Gateway entry vector with merlin Invitrogen IV 
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isoform 1 
pDEST-27 Gateway target vector containing 











Methods used in this study:  
METHOD USED IN STUDY 
 
Cytochalasin D treatment of cells I 
Subcellular fractionation I 
Flow and laser scanning cytometry I, II 
Cell culture I, II, III, IV 
Cell transfections I, II, III, IV 
Production of recombinant DNA constructs I, II, III, IV 
Cell cycle synchronization I, II, III 
Immunofluorescence and laser scanning confocal microscopy I, II, III, IV 
Western blot analysis and immunoblotting  I, II, III, IV 
Co-immunoprecipitation I, II, IV 
Insertion of random mutations by transposon insertion system II 
Primary culture of Schwann and schwannoma cells II, III 
Production of recombinant protein in E.coli II, III, IV 
Yeast two hybrid analysis II, IV 
Production of recombinant protein by in vitro translation II, III 
Site-specific mutagenesis of DNA constructs II, IV 
Protein affinity precipitation II, IV 
Tubulin purification from bovine brain  III 
Tubulin pull-down assay III 
Baculovirus production III 
Production of recombinant protein in insect cells III 
Fluorescence recovery after photobleaching (FRAP) III 
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Deconvolution and image analysis III 
In vitro and in vivo tubulin polymerization assay III 
Live cell imaging III, IV 
Adenovirus production III, IV 
In vitro phosphorylation assay III, IV 
Adenovirus infections III, IV 
Latrunculin B treatment of cells IV 
Production of recombinant protein in mammalian cells IV 
Wound healing assay IV 
Metabolic labeling of mammalian cells IV 
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RESULTS AND DISCUSSION 
1. Nucleo-cytoplasmic shuttling of merlin (I) 
In our earlier studies we had seen a subset of cells display nuclear localization of 
endogenous merlin. The vast majority of tumor suppressors localize to the nucleus, at 
least in some phases of the cell cycle (Fabbro & Henderson, 2003). Merlin, however, 
was considered a cytoskeletal tumor suppressor. Previous studies had shown that 
some rare isoforms of merlin localize to the nucleus (Kressel & Schmucker, 2002, 
Schmucker et al, 1999), however, these studies were done using merlin mutants that 
were later shown to be degraded by the ubiquitin-proteasome pathway (Gautreau et al, 
2002). We decided to study the localization of merlin further and used two different 
cell lines, U2OS osteosarcoma cells and U251 glioma cells, which contain detectable 
amounts of endogenous merlin (article I, Fig. 1 and 2). Since only 15% of the cells 
contained nuclear merlin we first studied whether we could increase the amount of 
merlin in the nucleus by inhibiting chromosome region maintenance 1 
(CRM1)/exportin-dependent nuclear export with Leptomycin B. This treatment 
increased the amount of nuclear merlin significantly, indicating that merlin is 
dependent on CRM1/exportin nuclear export (I, Fig. 3). As only a small subset of 
cells displayed nuclear localization in normal growth conditions, we wanted to see 
whether this is dependent on cell cycle stage or confluency. We tested this by 
synchronizing the cell cycle or growing cell cultures to confluency and analyzing the 
cells for nuclear merlin. According to our results merlin enters the nucleus after 
mitosis, at early G1 and leaves the nucleus as the G1 phase proceeds (I, Fig 4 and 5). 
Confluent cells were completely devoid of merlin. However, merlin still shuttled to 
the nucleus in these cells since Leptomycin B treatment caused merlin to accumulate 
into the nucleus. This indicates that the export rate of merlin exceeds that of the 
import rate in confluent cells.  
Mitotic cells have a round shape. After mitosis they gain their normal shape and 
adhere more firmly to the substratum, which reminds of the situation of cell adhesion. 
We therefore tested whether it is the adhesion that plays a role in the nuclear 
localization of merlin during cell cycle, not necessarily the cell cycle stage per se. 
Indeed we saw merlin localizing to the nucleus of adhering interphase cells, which 
would suggest that after mitosis, adherence induces merlin’s nuclear localization (I, 
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Fig. 7). However, in contrast to ERK, this localization was not dependent on an intact 
actin cytoskeleton (I, Fig. 8) since merlin localized to the nucleus of adhering cells 
even if the actin cytoskeleton was disrupted by Cytochalasin D treatment. We also 
studied whether merlin phosphorylation plays a role in nuclear shuttling. In nuclear 
extracts, both phosphorylated forms of merlin could be found, and stimulation of 
PKA or PAK did not inhibit nuclear localization, suggesting that nuclear localization 
is not, at least directly, regulated by phosphorylation of serine 518 (I, Fig. 6).  
Our finding that, like so many other tumor suppressor, also merlin localizes to the 
nucleus is interesting since merlin is considered to be an essential part of the 
cytoskeleton. Why would a cytoskeletal protein undergo nucleo-cytoplasmic 
shuttling? Of interest are results where merlin-binding partners such as paxillin, 
syntenin (Aplin & Juliano, 2001), PIKE-L (Rong et al, 2004b) and magicin/MED28 
(Lee et al, 2006b, Sato et al, 2004) have been shown to undergo nucleo-cytoplasmic 
shuttling or which have been implicated in transcriptional or translational regulation. 
For instance paxillin and syntenin have been shown to play a role in transcription 
(Aplin & Juliano, 2001), but it is unclear whether merlin regulates these functions. 
One possibility for studying whether merlin regulates paxillins nuclear functions, 
would be to inhibit the merlin-paxillin interaction. Paxillin has been shown to bind 
polyA-binding protein 1 (PABP1) and to enhance PABP1 bound mRNA export from 
the nucleus (Woods et al, 2005). Paxillin targets mRNA to focal adhesions, where 
protein translation takes place. Localized, efficient protein translation also has an 
important role in cell migration (Woods et al, 2005). If merlin plays a role in paxillin 
dependent mRNA transport, then either inhibiting the merlin-paxillin interaction or 
creating a stable merlin-paxillin interaction at the membrane, could have role in 
paxillin dependent mRNA transport, focal adhesion formation and cell migration. 
Recently, another binding partner of merlin, actin, was shown to localize to the 
nucleus and control gene expression (Vartiainen et al, 2007).  
The role of merlin in the nucleus and its nucleo-cytoplasmic shuttling is still unclear. 
However, increasing evidence suggests that the nucleus is not merely a convenient 
compartment where cytoskeletal proteins can be relocated when they are no longer 
needed in their more conventional locations (e.g. plasma membrane), but they also 
have other functions in the nucleus, perhaps independent from their cytoplasmic roles. 
In the case of merlin this could be tested by transfecting cells with a form of merlin, 
which contains a mutated cytoplasmic retention and nuclear export signals (Kressel & 
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Schmucker, 2002). This merlin would be trapped in the nucleus and its effects on cell 
cycle and migration could be studied. Another possibility would be to mutate 
merlin’s, yet unidentified, nuclear import signal.  
 
2. Interaction of merlin with a cell cycle-regulator HEI10 (II) 
In a yeast-two hybrid screen in search for merlin-interacting proteins, we identified a 
novel binding partner for merlin, a cyclin B-binding protein and cell cycle regulator 
HEI10 that has been shown to localize to the nucleus (Toby et al, 2003). Our aim was 
to study whether HEI10 could be a nuclear binding partner for merlin and to study the 
functional consequences of the merlin-HEI10 interaction.  HEI10 had been previously 
characterized as a protein capable of enhancing invasion in yeast. It is a cell cycle 
regulator both in yeast and mammals, controlling the accumulation of cyclin B. 
HEI10 is a 277 amino acid protein containing an N-terminal RING-finger motif, often 
found in E3 ubiquitin ligases, a coiled-coil domain and a C-terminal domain which is 
phosphorylated by cyclin B/Cdc2. HEI10 interacts with the UbcH7 E2 ubiquitin 
conjugating enzyme and with cyclin B and regulates its degradation (Toby et al, 
2003). A recent publication shows that HEI10 also negatively regulates cell migration 
and metastasis, as HEI10 depleted cells migrate and invade more efficiently than wild 
type cells. In addition, depletion of HEI10 in these cells results in upregulation of 
p130Cas, paxillin, Cdk1 and cyclin B2, but not merlin (Singh et al, 2007).  
We showed that merlin and HEI10 interact through their coiled-coil α-helical regions, 
which are domains frequently involved in protein interactions (II, Fig. 1-3). In 
addition, we analyzed merlin and HEI10 localization in U2OS osteosarcoma cells in 
which both proteins are expressed endogenously. The two proteins localize 
underneath the cell membrane during the entire cell cycle, and in a small subset of 
cell, they also colocalize in the nucleus (II, Fig. 4 and 5). HEI10 is expressed mostly 
in the nucleus (also during S-phase), whereas merlin and HEI10 colocalize in the 
nucleus only after mitosis at G1 and during cell attachment. We also studied whether 
merlin could influence HEI10 expression. In RT4-5-4 rat schwannoma cells and 
human Schwann (expressing merlin) and schwannoma (no merlin expression) cells 
that also express HEI10. Expression of merlin translocates HEI10 from the nucleus to 
the cell membrane (II, Fig. 6). In addition, we tested whether merlin expression 
influences HEI10 protein amount in 293HEK cells. When cells were transfected with 
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a mutant merlin lacking the C-terminus (merlin 1-547), the amount of HEI10 protein 
was reduced by 59% (P<0.01), and with the wild type protein, HEI10 amount was 
reduced by 23% (P<0.05). This degradation was seen after 72 hours of transfection 
(II, Fig. 7), which might indicate that merlin influences HEI10 degradation only when 
cells are beginning to reach contact inhibition of growth.  
In this study we identified HEI10, a cell cycle and cell migration regulator, as a 
merlin binding partner. This is the first potential binding partner for merlin in the 
nucleus, and the two proteins also colocalize during mitosis at the centrosomes. 
HEI10 regulates cell cycle by degrading cyclin B, whereas merlin regulates HEI10 
levels. This provides a link for merlin to cell cycle regulation, worth further 
investigation. It would be of interest to express a merlin construct that would 
stimulate constitutive HEI10 degradation, to see whether this would have any impact 
on cyclin B degradation or on cell cycle progression during mitosis. It is shown that 
depletion of HEI10 leads to enhanced motility and migration and up-regulation of 
several pro-motility genes (Singh et al, 2007). Does the depletion of the whole protein 
mimic the situation where its amount is regulated by degradation? Perhaps merlin is 
required for the regulation of HEI10, that it is then needed for efficient cyclin B 
degradation at the end of mitosis. This could be tested by studying MEF’s lacking 
merlin; do these cells have altered cell cycle or cyclin B levels with or without HEI10 
expression?  
Whether these two proteins act together at the membrane or in the nucleus to govern 
cell cycle progression, is still unknown. Our unpublished data shows that merlin and 
HEI10 could together influence cell cycle progression, by blocking the cell cycle 
either in G1 or S phase. Constitutively open merlin and HEI10 block the cell cycle in 
S phase, whereas wild type merlin together with HEI10 block it in G1 even more 
strongly than merlin alone. Another interesting piece of data is the finding that HEI10 
expression is different in tumors and in normal tissue. HEI10 is up-regulated in 
melanomas (Smith et al, 2004) and a translocation involving HEI10 has been reported 
in uterine leiomyoma (Mine et al, 2001). It would be of interest to study whether this 
up-regulation in HEI10 coincides with the lack of merlin in tumors.  
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3. Merlin regulates the microtubule cytoskeleton of primary 
Schwann cells (III) 
Another common feature of tumor suppressors, in addition to their nuclear 
localization, is their ability to localize to mitotic structures and to interact with 
microtubules (Fisk et al, 2002, Hergovich et al, 2003). For example Von Hippel 
Lindau tumor suppressor protein (pVHL) interacts with microtubules and stabilizes 
them against depolymerization. In addition, patient mutations residing in the tubulin-
binding area of pVHL influence its tubulin binding ability, suggesting that at least 
some of the patient phenotypes are caused by its inability to bind tubulin properly 
(Hergovich et al, 2003, Lolkema et al, 2004). We had previously seen merlin localize 
to mitotic structures (I, II) and this led us to study merlin in context with 
microtubules. Merlin has previously been shown to bind microtubules in vitro 
(Stokowski & Cox, 2000, Xu & Gutmann, 1998), however these studies have been 
controversial and no additional in vivo evidence has been presented. Therefore, we 
wanted to further investigate the merlin-tubulin interaction.  
In this study we identified two tubulin-binding sites in merlin, one in the N-terminus 
(aa 1-100) and other in the C-terminus (aa 492-547) of merlin (III, Fig. 2). We saw 
the two proteins colocalize in the centrosomes and mitotic spindle during mitosis and 
in the mid-body during cytokinesis in U251 glioma cells (III, Fig. 1). Merlin is able to 
form a closed conformation by intramolecular association, which blocks many of its 
binding sites (Grönholm et al, 1999). We therefore studied whether intramolecular 
association or serine 518 phosphorylation, thought to open the molecule, could 
regulate merlin-tubulin binding. Merlin’s intramolecular association, and also 
phosphorylation of the S518, inhibited merlin-tubulin binding, implicating a more 
complex mechanism for merlin activation than simply phosphorylation of S518 (III, 
Fig. 3). This would suggest that merlin exists in a conformation where it is open but 
unphosphorylated on S518.  
Many microtubule-associated proteins regulate tubulin polymerization and, according 
to this study, also merlin modulates microtubule polymerization in an in vitro assay 
by enhancing the rate of polymerization (III, Fig. 4). It is of interest, that the full-
length protein was required for this effect, whereas C-terminally deleted mutant 
merlin (aa 1-547) could not induce polymerization, even though it contains both 
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identified tubulin binding sites, which further shows the importance of the correct 
regulation of merlin.  
To gain further in vivo insight in the merlin-tubulin interaction we used Nf2 -/- 
primary mouse Schwann cells (Giovannini et al, 2000). In these cells no clear 
colocalization with adeno-infected wild type merlin and tubulin could be seen. Only 
partial colocalization was seen under the cell membrane where both proteins resided 
(III, Fig. 1). However, when these cells lost merlin, their microtubule cytoskeleton 
became disorganized, and the cell morphology changed dramatically (Fig. 9); the cells 
lost their spindle shape and obtained a more spread morphology (III, Fig. 5).  
 
 
Figure 9. Mouse schwann cells expressing merlin (left) and lacking merlin (right). α-tubulin 
staining, 1000x magnification. 
 
This change in the microtubule cytoskeleton is probably due to differences in 
microtubule dynamics, which has been shown previously to be responsible for fluid 
sheer stress dependent cell shape change (Malek & Izumo, 1996). The Nf2 -/- 
Schwann cells contained more soluble tubulin in Triton-X 100 lysates. However, the 
overall tubulin amount in -/- and merlin expressing cells was similar when analyzed 
from 6M Urea lysates (III, Fig. 5). This might suggest that more tubulin is associated 
with microtubules in merlin expressing cells. We then tested whether merlin enhances 
microtubule polymerization also in vivo. Merlin expression increased the tubulin 
polymerization rates in Schwann cells treated with Nocodazole, a drug that 
depolymerizes microtubules, since they were able to re-polymerize their microtubules 
faster than the -/- cells. Using FRAP-analysis we could also see that merlin expressing 
Schwann cells had enhanced microtubule dynamics (III, Fig. 6).  
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According to our study, merlin-tubulin binding is under strict regulation. These 
proteins colocalize only briefly and it still remains unclear if this interaction affects 
merlin’s tumor suppressor function. One possibility is in the regulation of 
endocytosis. Microtubules regulate endocytic pathways (Murray & Wolkoff, 2003, 
Petiot et al, 2003) and it has been shown that also merlin plays a role in endocytic 
processes by localizing to endocytic structures and regulating growth factor receptor 
availability (Fraenzer et al, 2003, Lloyd et al, 2002, Maitra et al, 2006, Scoles et al, 
2000, Curto et al, 2007). Endocytic processes regulate growth-factor availability and 
recycling, and it has been shown that also microtubules play a role in these processes. 
Fast and slow microtubules sort their vesicles into different compartments, fast ones 
more often deliver their cargo to lysosomes for degradation than the slow ones. This 
rapid movement and maturation is completely dependent on microtubules; if 
microtubules are disrupted, the dynamic vesicles will non-selectively join all early 
endosomes and are less efficiently degraded (Lakadamyali et al, 2006). We 
hypothesize that merlin could function as a linker at the plasma membrane, helping 
receptor-containing endocytosed vesicles to attach to microtubules. In cells lacking 
merlin, this receptor recycling might be slower, and the growth factor receptors would 
be cleared from the membrane less efficiently. Merlin could have a dual role at the 
membrane of Schwann cells, partly by transferring early endocytic vesicles to 
microtubules and partly by increasing the microtubule polymerization rate, thus 
guiding them to lysosomes. Nf2 -/- and add-back Schwann cells have differences in 
their growth factor receptor recycling rates (D. Lallemand, manuscript). If the merlin-
tubulin interplay is important for clearing up the receptors one would hypothesize that 
Nocodazole treatment would increase the amount of receptors at the membrane of 
both Schwann cell lines. However, if merlin alone is responsible for this receptor 
recycling, the Nf2 -/- cells would still have more receptors at their membrane.  
As we did not see disorganized microtubules in any other cell types lacking merlin, 
this might be a way for merlin to specifically regulate Schwann cell proliferation.  
 
4. Phosphorylation of merlin N-terminus by PKA (IV)  
Our previous studies had identified a PKA phosphorylation site in the merlin FERM-
domain, in addition to the previously described C-terminal site (Alfthan et al, 2004). 
It has also been shown that PKA activity increases the proliferation rate of Schwann 
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cell (Kim et al, 1997). For these reasons we wanted to study PKA mediated merlin 
phosphorylation further.  
In our study we identified serine 10 (S10) as the N-terminal phosphorylation site. In 
addition to S10 and S518, no additional PKA phosphorylation sites were found (IV, 
Fig. 1). We studied whether S10 phosphorylation affects S518 phosphorylation, but 
could not see any effect when serine 10 was mutated either to alanine (A) or aspartic 
acid (D) (IV, Fig. 2), mimicking the unphosphorylated and phosphorylated residue, 
respectively. S518 phosphorylation has been shown to promote heterodimerization 
with ezrin (Alfthan et al, 2004). However, merlin phosphorylated at S10 bound ezrin 
similarly as unphosphorylated merlin (IV, Fig. 1).  
The first 18 amino acids are unique to merlin. They are not included in the FERM 
domain, and are indicated in the merlin binding of actin (Brault et al, 2001). 
Therefore, we hypothesized that N-terminal phosphorylation could play a role in the 
modulation of the merlin-actin interaction. Our first clue came from transfection 
experiments where merlin S10 mutants induced more diverse morphologies than did 
the wild type merlin in COS-7 and Nf2 -/- MEFs (IV, Fig. 3). Cells transfected with 
merlin wild type had an increased amount of membrane extensions compared to 
untransfected cells, whereas cells expressing merlin S10A displayed much elongated 
extensions not seen with wild type merlin or S10D. S10D transfection resulted in a 
different phenotype, producing short filopodia-like structures and rarely long 
extensions seen with S10A. When the same experiment was performed with merlin 
isoform II the phenotypes were even more pronounced (IV, Fig. 3), which is of 
interest as it is shown to bind actin more strongly than the wild-type merlin (James et 
al, 2001).  
We next studied the F-actin structures in transfected Nf2 -/- MEFs (IV, Fig. 4). Cells 
expressing wild type merlin had a dense, fine network of actin in lamellipodia areas. 
The actin meshwork structure was seen in wild type, S10D and S518A transfected 
cells; however, in S10A transfected cells the F-actin staining was reduced compared 
to wild type or S10D cells and the meshwork was missing. Since it has been shown 
that merlin can stabilize actin filaments (James et al, 2001) we then tested whether 
merlin mutants could protect F-actin from Latrunculin B treatment (an agent that 
inhibits actin polymerization). We noticed that cells expressing S10D were more 
resistant to the depolymerizing effect of Latrunculin B than cells with wild type or 
S10A merlin (IV, Fig. 5). We then studied whether S10 plays a role in cell motility. 
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When MEFs were transfected with various merlin constructs, cells expressing merlin 
S10A were unable to produce lamellipodia and migrated slower (IV, Fig. 6).  
One of merlin’s actin binding sites lies within the first 18 amino acids, however, when 
we tested merlin S10A ability to directly bind actin it was not affected (unpublished 
data). Therefore we hypothesize that it must be through a different mechanism than 
direct actin binding, that S10 phosphorylation of merlin affects cytoskeletal 
organization, lamellipodia formation and migration. This effect could be mediated 
through merlin’s binding partners involved in the regulation of actin dynamics; the 
most promising candidates are β-spectrin, paxillin, N-WASP and ERM-proteins, or 
through the Rac-signaling pathway, but this requires further study. It will be of 
interest to study how S10A mutant affects the interplay between merlin and its 
binding partners.  
 
 51 
CONCLUDING REMARKS  
AND FUTURE PERSPECTIVES 
This study began in 2002 with the observation on merlin’s surprising subcellular 
localization in the nucleus and centrosomes. This direction of research seemed a bit 
hazardous at the time as most research efforts were targeted to identifying kinases 
phosphorylating merlin, mechanisms for its membrane:cytoskeleton interaction, and 
how these interactions modulated merlin’s tumor suppressor activity. Since then, the 
areas of merlin research have vastly expanded, now covering various aspects of 
cellular functions that merlin is able to regulate, and identifying more and more 
interaction partners for merlin. It is now acknowledged that merlin has a versatile role 
in cells, perhaps depending on cell type or developmental stage of the organism.  
 
The studies presented in this thesis have expanded merlin’s role and found alternative 
functions that might explain why schwannomas are the typical hallmark of the NF2 
disease. Our studies have shown that merlin actively shuttles in and out of the nucleus 
(I), and more and more evidence is published, showing nuclear localization of merlin 
binding partners (Aplin & Juliano, 2001, Rong et al, 2004b, Vartiainen et al, 2007). 
Unfortunately our research efforts have still not answered the question of what the 
functional consequence of merlin’s nucleo-cytoplasmic shuttling might be. We 
hypothesize that merlin could regulate the localization of nuclear binding partners, 
perhaps retaining them in or transporting them to the cytoplasm. In the case of HEI10 
this could be studied by identifying and mutating the nuclear import signal in merlin, 
to see whether this influences HEI10 localization and/or function. Alternatively, 
merlin could, as a cytoskeletal scaffolding protein, participate in re-building the 
nuclear envelope, after cell division, based on its nuclear localization at G1. To this 
point we have no evidence that merlin itself would bind RNA or DNA directly, but 
this needs further investigation. In our study of the HEI10-merlin interaction, we 
discovered that these two proteins can localize to the nucleus simultaneously, 
however, so far we have no data showing their interaction in the nucleus, since these 
experiments have been technically difficult to perform. We could only show that 
merlin can influence HEI10 protein levels and localization, retaining it at the 
membrane. There are not many studies published on HEI10, but recently Singh et al. 
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(2007) showed that depletion of HEI10 enhances cell migration by the upregulation of 
cyclin B/Cdk1. They hypothesize that merlin could relocate HEI10 in cells so that it 
would not be able to enhance migration (Singh et al, 2007). Our merlin-HEI10 study 
connects cyclin B to merlin. As cyclin B/Cdk1 regulates passage through M phase 
and merlin is not shown to influence the progression of mitosis it is unlikely that 
merlin would regulate this aspect of HEI10 function. However, our preliminary 
results show that merlin has some role in mitosis or alternatively in centrosome 
replication as 293HEK cells expressing constitutively open merlin display increased 
amount of multipolar spindles. Whether this is through a direct mechanism or through 
HEI10 is still unknown, as no role for HEI10 in causing spindle abnormalities has 
been shown. It is perhaps more likely that merlin affects other HEI10 mediated 
functions, such as migration or metastasis, linking the proteins to tumor formation.  
The third study in this thesis expanded our early notions of merlin’s localization to 
mitotic structures. This work showed for the first time, that merlin influences 
microtubules, their structure and dynamics. The finding is important, since 
microtubules are involved in various cellular processes, including cell growth and 
division. What makes this finding even more intriguing is that we could only see 
microtubule disorganization in primary Schwann cells lacking merlin, indicating that 
merlin has an important role in regulating Schwann cell microtubule cytoskeleton. 
This may partly explain the presence of such specific tumors, vestibular 
schwannomas, in NF2 patients. However, the link between merlin, microtubule 
organization and membrane traffic still needs to be clarified.  
Finally, the fourth study in this thesis identified a novel phosphorylation site in 
merlin. This phosphorylation seems to regulate merlin’s impact on the actin 
cytoskeleton. The finding is interesting as the first 18 amino acids containing the 
phosphorylated serine are not included in the FERM-domain. We believe that the 
extreme N-terminal residues could form a flexible tail that participates in regulating 
binding to interacting partners, depending on its phosphorylation status. Our 
experiments suggest that this tail does not modulate actin cytoskeleton directly as we 
could not see any difference in actin binding of the phosphorylated vs. 
unphosphorylated N-terminus. However, merlin has several binding partners that are 
able to modulate actin cytoskeleton, and it might be that it is through these binding 
partners that merlin regulates lamellipodia formation. Another interesting aspect is 
that merlin regulates PAK (Kissil et al, 2003), Rac and Ras activity (Morrison et al, 
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2007), which provides another link to cytoskeletal regulation. It will be interesting to 
study, through which pathway the S10 phosphorylation performs its role.  
 
Despite the progress in NF2 research, we are still lacking specific treatment for the 
NF2 disease. This thesis work has widened the field and brought upon new avenues of 
research that may eventually offer new therapeutic targets in the fight against NF2 
disease. In the beginning of a study it is hard to evaluate the relevance of its outcome. 
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